In 2015, we saw the crescendo of the Amgen versus Sandoz case after many months of appeals. Along with that legal case, much more is still ongoing in the biosimilar sector. This year also provided a milestone in the ongoing discussions and debates on naming conventions with both the US FDA and WHO providing their individual guidance on such issues.
But what does all this mean for future biosimilar development?
Many questions need answering in order for biosimilars to reach the market success that the industry knows it can attain.
Across two days, industry and thought-leading speakers from across the globe will come together at World Biosimilar Congress 2016 to meet and discuss pertinent topics on biosimilar drug development and healthcare uptake:
We are excited to bring together representatives from across the whole value chain who can and are working together to ensure that we are providing cost-effective biologics for payers, prescribers and patients. We hope you can join us in November and look forward to seeing you there.
For more information, click here